Stewart W A, Acott P D, Salisbury S R, Lang B A
Izaak Walton Killam Health Centre, 5850 University Avenue, Halifax, Nova Scotia B3J 3G9, Canada.
Arthritis Rheum. 2003 Aug;48(8):2294-8. doi: 10.1002/art.11211.
To determine the bone mineral density (BMD) status of our juvenile dermatomyositis (DM) population and to compare the frequency of osteopenia in patients with active disease requiring corticosteroids with that in patients with inactive disease who are not receiving corticosteroids.
Medical charts of all children diagnosed as having juvenile DM at our institution between 1989 and 1999 were reviewed for demographic and clinical data, including disease activity and duration of corticosteroid therapy. BMD measurements of the lumbar spine (L1-L4) were performed using dual x-ray absorptiometry (DXA). Z scores were calculated from the BMD data for comparison with published normative data.
A total of 15 patients were assessed: 10 with active disease, and 5 with inactive disease who had not taken corticosteroids for an average of 6.0 years (range 3.4-8.1 years). Baseline BMD measurements demonstrated osteopenia or frank osteoporosis in the majority of patients, including 6 of the 10 patients with active disease and 4 of the 5 patients whose disease was in remission. Fourteen patients had serial BMD measurements. Persistent or worsening osteopenia was documented in all patients who had ongoing active disease, except for 3 patients who had been treated with bisphosphonates because of vertebral compression fractures.
Osteopenia is common in patients with juvenile DM, and it usually worsens with ongoing disease. It can persist for many years after the disease enters remission. Bisphosphonates appeared to beneficially affect bone mineralization in our patients. Treatment to prevent the long-term complications of osteoporosis in patients with juvenile DM should be considered and requires further study.
确定青少年皮肌炎(DM)患者的骨矿物质密度(BMD)状况,并比较需要使用皮质类固醇治疗的活动性疾病患者与未接受皮质类固醇治疗的非活动性疾病患者的骨质减少频率。
回顾了1989年至1999年间在我们机构诊断为青少年DM的所有儿童的病历,以获取人口统计学和临床数据,包括疾病活动度和皮质类固醇治疗持续时间。使用双能X线吸收法(DXA)对腰椎(L1-L4)进行BMD测量。根据BMD数据计算Z评分,以便与已发表的标准数据进行比较。
共评估了15例患者:10例患有活动性疾病,5例患有非活动性疾病,这些患者平均6.0年(范围3.4-8.1年)未服用皮质类固醇。基线BMD测量显示大多数患者存在骨质减少或明显骨质疏松,包括10例活动性疾病患者中的6例和5例疾病缓解患者中的4例。14例患者进行了连续BMD测量。除3例因椎体压缩骨折接受双膦酸盐治疗的患者外,所有患有持续性活动性疾病的患者均记录有持续性或恶化的骨质减少。
骨质减少在青少年DM患者中很常见,并且通常会随着疾病的持续而恶化。在疾病进入缓解期后,骨质减少可能会持续多年。双膦酸盐似乎对我们患者的骨矿化有有益影响。应考虑对青少年DM患者进行治疗以预防骨质疏松症的长期并发症,这需要进一步研究。